The pharmacokinetics of cefuroxime axetil suspension in 28 infants and children, ranging in age from 3 months to 12 years (mean, 23 months), were studied. Mean maximum serum cefuroxime concentrations of 3.3, 5.1, and 7.0 ,ug/ml were achieved 3.6, 2.7, and 3.1 h after the administration of doses of 10, 15, and 20 mg, respectively, of cefuroxime axetil suspension per kg of body weight together with milk or milk formula. These concentrations exceed the MICs for common respiratory tract pathogens, including j8-lactamase-producing strains of Haemophilus influenzae and Moraxella (Branhamella) catarrhalis. Following a 10-or 15-mg/kg dose, serum cefuroxime concentrations are similar to those achieved in adults following the administration of a 250-mg cefuroxime axetil tablet. There were linear relationships between dose and both maximum serum cefuroxime concentration and area under the serum drug concentration-versus-time curve. The mean half-life of cefuroxime in serum was independent of dose and ranged from 1.4 to 1.9 h. No cefuroxime axetil (intact ester) was detected in the blood. The intact ester in the urine of four children was measured; however, the amount recovered represented less than 0.1% of the administered dose.
Cefuroxime axetil is the orally absorbed ester prodrug of the cephalosporin cefuroxime sodium. Since cefuroxime sodium is not absorbed orally (4), the 1-acetyloxyethyl ester was substituted for sodium on the cefuroxime molecule to increase its lipid solubility and improve its gastrointestinal absorption. After oral administration, cefuroxime axetil is absorbed and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and portal blood (10) to produce concentrations of cefuroxime that exceed the MIC of common respiratory tract pathogens, including 3-lactamasepositive and -negative strains (1, 11, 12, 17) .
A suspension formulation of cefuroxime axetil has been developed to facilitate the administration of cefuroxime axetil to pediatric patients. In healthy adult volunteers, the suspension formulation of cefuroxime axetil is less bioavailable than the tablet formulation (8) . The purpose of this study was to evaluate the pharmacokinetics of cefuroxime axetil suspension in infants and children.
MATERIALS AND METHODS
Pediatric patients, aged 3 months to 12 years, with infections which required systemic antibiotic therapy and for which cefuroxime axetil suspension was considered to be appropriate treatment were eligible for this open-label, randomized, parallel-group study. Patients receiving parenteral antibiotics for whom conversion to oral therapy was being considered were included in the study. Patients (3) . Therefore, the 3-h blood sample was also used to determine whether cefuroxime axetil (intact ester) was present in whole blood. Immediately after collection of the 3-h blood sample, 1 oxime concentrations of 0.15, 1.5, and 15 ,ug/ml, respectively. The interday coefficients of variation were 10.9, 3.8, and 6.3% for cefuroxime concentrations of 0.15, 1.5, and 15 ,ug/ml, respectively. Quantitation of cefuroxime axetil in blood and urine. Acetonitrile-ethanol extracts of the 3-h blood samples were assayed as previously described (10) for cefuroxime axetil by an HPLC procedure. The limit of quantitation was 0.25 ,ug/ml. Urine obtained from patients was directly assayed for cefuroxime axetil by a similar method. The limit of quantitation was 0.125 pg/ml.
Pharmacokinetic calculations. Pharmacokinetic parameters evaluated included maximum observed serum cefuroxime concentration (Cmax), time to maximum serum cefuroxime concentration (Tmax), area under the serum drug concentration-versus-time curve to the last time point (AUC,,_,), area under the serum drug concentration-versustime curve from time zero to infinity (AUC,,), and elimination half-life (01/2).
Since some patients received a parenteral dose of cefuroxime sodium before study enrollment, concentrations (C) measured after the first dose of cefuroxime axetil suspension were adjusted by the principle of superposition (5) oxime axetil detected in the urine ranged from 21.7 to 240.8 jig, which represented less than 0.1% of the total dose administered.
DISCUSSION
The pharmacokinetics of cefuroxime axetil suspension in infants and children are similar to the pharmacokinetics of cefuroxime axetil tablets in adults. Although the suspension formulation of cefuroxime axetil is less bioavailable than the tablet formulation, the Cmax achieved in pediatric patients receiving a 10-or 15-mg/kg dose of cefuroxime axetil suspension is similar to the Cmax reported for adults receiving a single 250-mg cefuroxime axetil tablet (3) . Following the administration of a 20-mg/kg dose of cefuroxime axetil suspension to pediatric patients, the Cmax was similar to the Cm. observed in adults receiving a single 500-mg cefuroxime axetil tablet (3, 19) . The Cmax observed in our patients receiving 15-or 20-mg/kg doses of cefuroxime axetil suspension was nearly identical to concentrations observed in children receiving crushed cefuroxime axetil tablets suspended in 85% sucrose at identical doses (7) .
Both Cmax and AUC increased proportionately with dose over the dose range of 10 to 20 mg/kg. This finding is identical to that observed with cefuroxime axetil tablets for adults. Twelve healthy adults participated in a study (3) designed to evaluate the dose proportionality of four oral doses of cefuroxime axetil (125, 250, 500, and 1,000 mg) administered after a meal. Linear relationships between the dose of cefuroxime axetil and both Cmax and AUC were demonstrated. The enhanced absorption of cefuroxime axetil in the presence of food, as observed by Finn et al. (3) , is in agreement with the results of other studies (7, 10, 19) . On the basis of these findings, we decided to administer cefuroxime axetil suspension with milk or milk formula in the present study.
The MIC of cefuroxime for 90% of 3-lactamase-positive strains of Haemophilus influenzae and Moraxella (Branhamella) catarrhalis is 1.0 ,g/ml, and the MIC of cefuroxime for 90%o of tested strains of most common respiratory tract pathogens is far below this concentration (12) . The amount of time during which the serum cefuroxime concentration exceeded 1 ,ug/ml increased with increasing doses of cefuroxime axetil suspension in infants and children. In addition, the mean t1/2 of cefuroxime was independent of dose and ranged from 1.4 to 1.9 h. This is longer than the t1/2s of cefaclor (42.5 min), cephalexin (0.98 h), and cephradine (1.0 h) in pediatric patients and slightly longer than the mean tl2 (range, 1.1 to 1.4 h) observed for children receiving crushed cefuroxime axetil tablets (6, 7, 13, 14) . Cefuroxime axetil tablets administered twice daily have proved effective in the treatment of otitis media (2, 15) and group A streptococcal pharyngitis (9, 18) in infants and children. Since 10-or 15-mg/kg doses of cefuroxime axetil suspension produce serum cefuroxime concentrations similar to those observed after administration of a 250-mg cefuroxime axetil tablet, it is likely that cefuroxime axetil suspension will be efficacious when administered twice daily. Clinical trials with cefuroxime axetil suspension have confirmed the effectiveness of these doses with twice-daily dosing in otherwise healthy patients with mild to moderate infections caused by susceptible pathogens (8) .
In the present study, cefuroxime axetil (intact ester) was not detected in the systemic circulation of infants and children. This is in agreement with results obtained with healthy adults (10) and confirms that cefuroxime axetil is rapidly hydrolyzed to cefuroxime, the microbiologically active form of the drug. Cefuroxime axetil (intact ester) was detected in the urine of four children; however, the amount recovered was less than 0.1% of the administered dose. Taken together, these results indicate that in children hydrolysis of cefuroxime axetil to active drug is rapid, with little prodrug excreted unchanged. Unlike cefuroxime axetil, some antibiotic prodrugs are excreted by the kidneys before they can be hydrolyzed to the microbiologically active form. We reported earlier that the bioavailability of chloramphenicol following the administration of intravenous chloramphenicol succinate was extremely variable in infants and children (16) . The urinary recovery of unchanged chloramphenicol succinate ranged from 7 to 42% of the administered dose.
We conclude that serum cefuroxime concentrations and the area under the serum cefuroxime concentration-versustime curve increase with dose in a linear fashion and that the observed serum cefuroxime concentrations exceed the MIC for common respiratory tract pathogens, including P-lactamase-producing strains. In addition, cefuroxime axetil is rapidly hydrolyzed to its active moiety, cefuroxime, in infants and children.
